Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Austria

Research and Innovation Action · Running

EAVI European-african Vaccine Initiative (eavi): Accelerating Preventive Measures Against Chikungunya Virus in Sub-saharan Africa

Coordinator
Medizinische Universitat Innsbruck, Austria
Runs
1 May 2026 to 30 April 2031
Status
Running
EU funding
€13.7m
Total cost
€14.0m
Partners
8 organisations in 7 countries
Type
Research and Innovation Action
Grant agreement
101249075

What the project is doing

In the project's own words, from its summary on CORDIS.

Access to vaccines against neglected tropical diseases (NTDs) is limited in sub-Saharan Africa (SSA), where NTD burdens are high, while vaccine trials often are performed in Western populations. There is an urgent need to test, license and distribute vaccines in SSA populations at risk of NTDs, especially vulnerable groups like those with co-infections. The European-African vaccine initiative (EAVI) closes this gap by developing a European-African vaccine partnership to evaluate the safety, immunogenicity, and efficacy of prophylactic vaccines against NTDs in SSA.

As a proof of concept, EAVI will evaluate a live-attenuated Chikungunya virus (CHIKV) vaccine—licensed in EU, Canada, UK, and Brazil—in healthy and in vulnerable HIV-positive adults in Africa. To achieve this, we will: 1. perform a two-armed clinical phase IIIb clinical trial in Kenya and Tanzania with rigorous safety and immunogenicity endpoints; 2. carry out in-depth immune-profiling using gold-standard and beyond state-of-the-art methodology; 3. integrate prevention and surveillance through enhanced diagnostics and One Health prospective serosurvey in humans and vector monitoring; 4. foster technology transfer, capacity building, and training in SSA as well as strategic partnerships for robust stakeholder and community engagement and uptake.

EAVI’s multidisciplinary expertise of clinicians, social scientists, statisticians, epidemiologists, immunologists, virologists, and vaccine manufacturers provides proven experience in implementing complex clinical trials in SSA, including in people living with HIV, and the most innovative immune-profiling technologies to leverage the full potential of the trial. It will pave the way toward access of the CHIKV vaccine in SSA to fight this NTD as well as a roadmap for future trials of other NTD vaccines, in healthy, HIV-positive and other vulnerable populations in SSA.

Who is involved

OrganisationCityCountryRole
Medizinische Universitat InnsbruckInnsbruckAustriaCoordinator
Valneva Austria GmbHWienAustriaParticipant
Ecole Polytechnique Federale De LausanneLausanneSwitzerlandParticipant
Instituto De Salud Carlos IiiMadridSpainParticipant
Pikado WritingSaint EustacheFranceParticipant
Kenya Medical Research InstituteNairobiKenyaParticipant
Karolinska InstitutetStockholmSwedenParticipant
The Registered Trustees of the Ifakara Health InstituteDar Es SalaamTZParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI